@article{c1e359451ecc47ce98c20c35217063da,
title = "A possible role of FANCM mutations in male breast cancer susceptibility: Results from a multicenter study in Italy",
abstract = "Introduction Breast cancer (BC) in men is a rare disease, whose etiology appears to be associated with genetic factors. Inherited mutations in BRCA1/2 genes account for about 10–15% of all cases. FANCM, functionally linked to BRCA1/2, has been suggested as a novel BC susceptibility gene. Our aim was to test if FANCM germline mutations could further explain male BC (MBC) susceptibility. Methods We screened the entire coding region of FANCM in 286 MBCs by a multi-gene panel analysis, and compared these data with available whole exome sequencing data from 415 men used as population controls. Moreover, we genotyped the two most frequent FANCM mutations (c.5101C>T and c.5791C>T) in 506 MBCs and 854 healthy male controls. Results Two FANCM truncating mutations, the c.1432C>T (p.Arg478Ter) and c.1972C>T (p.Arg658Ter), were identified in two MBC cases (0.7%). When specifically considering cases at increased genetic risk for BC, FANCM mutation frequency raises up to 1%. One mutation, the c.2201_2202delCT (p.Ser734Terfs), was found among controls (0.24%). Mutation frequency in cases was higher than in controls, however this difference was not statistically significant. FANCM c.5101C>T was not present in any of the cases and controls analyzed, whereas FANCM c.5791C>T was found in two controls (0.23%). Conclusion Rare FANCM truncating mutations, other than c.5101C>T and c.5791C>T, may have a role in MBC susceptibility. The inclusion of FANCM in gene panels for research purpose would allow for the identification of a higher number of mutation carriers, thus helping estimate BC risk associated with FANCM mutations. {\textcopyright} 2017",
keywords = "BRCA1/2, Breast cancer susceptibility, FANCM, Germline mutations, Male breast cancer, arginine, cytosine, serine, thymine, DNA helicase, FANCM protein, human, tumor marker, adult, aged, Article, breast cancer, cancer susceptibility, controlled study, FANCM gene, gene frequency, gene function, genetic code, genetic identification, genetic risk, genetic screening, germline mutation, heterozygote, human, Italy, major clinical study, male, multicenter study (topic), mutation rate, mutational analysis, population research, priority journal, tumor suppressor gene, very elderly, whole exome sequencing, breast tumor, case control study, clinical trial, genetic predisposition, genetics, genotype, middle aged, multicenter study, risk factor, whole genome sequencing, young adult, Adult, Aged, Aged, 80 and over, Biomarkers, Tumor, Breast Neoplasms, Male, Case-Control Studies, DNA Helicases, Genetic Predisposition to Disease, Genotype, Germ-Line Mutation, Humans, Male, Middle Aged, Risk Factors, Whole Genome Sequencing, Young Adult",
author = "V. Silvestri and P. Rizzolo and V. Zelli and V. Valentini and I. Zanna and S. Bianchi and M.G. Tibiletti and L. Varesco and A. Russo and S. Tommasi and A. Coppa and C. Capalbo and D. Calistri and A. Viel and L. Cortesi and S. Manoukian and B. Bonanni and M. Montagna and D. Palli and P. Radice and P. Peterlongo and L. Ottini",
note = "Cited By :3 Export Date: 5 February 2019 CODEN: BREAE Correspondence Address: Ottini, L.; Dept. of Molecular Medicine, “Sapienza” University of Rome, Viale Regina Elena, 324, Italy; email: laura.ottini@uniroma1.it Chemicals/CAS: arginine, 1119-34-2, 15595-35-4, 7004-12-8, 74-79-3; cytosine, 71-30-7; serine, 56-45-1, 6898-95-9; thymine, 65-71-4; DNA helicase; transcriptional regulator ATRX; Werner syndrome ATP dependent helicase; Biomarkers, Tumor; DNA Helicases; FANCM protein, human Funding details: Istituto Toscano Tumori, ITT, ITT-2010 Funding details: Associazione Italiana per la Ricerca sul Cancro, AIRC, AIRC-IG16933 Funding text 1: This work was supported by Italian Association for Cancer Research (grant number AIRC-IG16933 ) to LO and by Istituto Toscano Tumori (grant number ITT-2010 ) to DP. The funder had no role in the design and conduct of the study; collection, management, analysis and interpretation of data; preparation, review, or approval of the manuscript, and decision to submit the manuscript for publication. We thank Dr. Giovanni Chillemi (Inter University Consortium for Super Computing - CINECA, Rome, Italy) for helpful discussion; Dr. Marco Tartaglia (Bambino Ges{\`u} Children's Hospital, Rome, Italy) and Dr. Alessandro Bruselles (Istituto Superiore di Sanit{\`a}, Rome, Italy) who provided frequency data on a population of more than 400 male exomic samples. References: Rizzolo, P., Silvestri, V., Tommasi, S., Pinto, R., Danza, K., Falchetti, M., Male breast cancer: genetics, epigenetics, and ethical aspects (2013) Ann Oncol, 24. , viii75-82; Silvestri, V., Zelli, V., Valentini, V., Rizzolo, P., Navazio, A.S., Coppa, A., Whole-exome sequencing and targeted gene sequencing provide insights into the role of PALB2 as a male breast cancer susceptibility gene (2017) Cancer, 123 (2), pp. 210-218; Katsuki, Y., Takata, M., Defects in homologous recombination repair behind the human diseases: FA and HBOC (2016) Endocr Relat Cancer, 23 (10), pp. T19-T37; Kiiski, J.I., Pelttari, L.M., Khan, S., Freysteinsdottir, E.S., Reynisdottir, I., Hart, S.N., Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer (2014) Proc Natl Acad Sci U. S. A., 111 (42), pp. 15172-15177; Peterlongo, P., Catucci, I., Colombo, M., Caleca, L., Mucaki, E., Bogliolo, M., FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor (2015) Hum Mol Genet, 24 (18), pp. 5345-5355; Neidhardt, G., Hauke, J., Ramser, J., Gro{\ss}, E., Gehrig, A., M{\"u}ller, C.R., Association between loss-of-function mutations within the FANCM gene and early-onset familial breast cancer (2017) JAMA Oncol, 3 (9), pp. 1245-1248; Catucci, I., Osorio, A., Arver, B., Neidhardt, G., Bogliolo, M., Zanardi, F., Individuals with FANCM biallelic mutations do not develop Fanconi anemia, but show risk for breast cancer, chemotherapy toxicity and may display chromosome fragility (2017) Genet Med; Silvestri, V., Rizzolo, P., Scarn{\`o}, M., Chillemi, G., Navazio, A.S., Valentini, V., Novel and known genetic variants for male breast cancer risk at 8q24.21, 9p21.3, 11q13.3 and 14q24.1: results from a multicenter study in Italy (2015) Eur J Cancer, 51 (16), pp. 2289-2295; Ottini, L., Silvestri, V., Rizzolo, P., Falchetti, M., Zanna, I., Saieva, C., Clinical and pathologic characteristics of BRCA-positive and BRCA-negative male breast cancer patients: results from a collaborative multicenter study in Italy (2012) Breast Cancer Res Treat, 134 (1), pp. 411-418; Rizzolo, P., Silvestri, V., Ottini, L., Retesting BRCA1/BRCA2 mutation negative male breast cancer patients using next generation sequencing technologies (2017) Breast Cancer Res Treat, 162 (1), pp. 199-200; Ottini, L., Silvestri, V., Saieva, C., Rizzolo, P., Zanna, I., Falchetti, M., Association of low-penetrance alleles with male breast cancer risk and clinicopathological characteristics: results from a multicenter study in Italy (2013) Breast Cancer Res Treat, 138 (3), pp. 861-868; Nielsen, F.C., van Overeem Hansen, T., S{\o}rensen, C.S., Hereditary breast and ovarian cancer: new genes in confined pathways (2016) Nat Rev Cancer, 16 (9), pp. 599-612; Pritzlaff, M., Summerour, P., McFarland, R., Li, S., Reineke, P., Dolinsky, J.S., Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results (2017) Breast Cancer Res Treat, 161 (3), pp. 575-586; Khoury, T., Hu, Q., Liu, S., Wang, J., Intracystic papillary carcinoma of breast: interrelationship with in situ and invasive carcinoma and a proposal of pathogenesis: array comparative genomic hybridization study of 14 cases (2014) Mod Pathol, 27 (2), pp. 194-203; Gracia-Aznarez, F.J., Fernandez, V., Pita, G., Peterlongo, P., Dominguez, O., de la Hoya, M., Whole exome sequencing suggests much of non-BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles (2013) PLoS One, 8 (2); Rashid, M.U., Muhammad, N., Khan, F.A., Hamann, U., Absence of the FANCM c.5101C>T mutation in BRCA1/2-negative triple-negative breast cancer patients from Pakistan (2015) Breast Cancer Res Treat, 152 (1), pp. 229-230; Hallamies, S., Pelttari, L.M., Poikonen-Saksela, P., Jekunen, A., Jukkola-Vuorinen, A., Auvinen, P., CHEK2 c.1100delC mutation is associated with an increased risk for male breast cancer in Finnish patient population (2017) BMC Cancer, 17 (1), p. 620; Johansson, I., Killander, F., Linderholm, B., Hedenfalk, I., Molecular profiling of male breast cancer – lost in translation? (2014) Int J Biochem Cell Biol, 53, pp. 526-535; Silvestri, V., Barrowdale, D., Mulligan, A.M., Neuhausen, S.L., Fox, S., Karlan, B.Y., Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2 (2016) Breast Cancer Res, 18 (1), p. 15; Dicks, E., Song, H., Ramus, S.J., Van Oudenhove, E., Tyrer, J.P., Intermaggio, M.P., Germline whole exome sequencing and large-scale replication identifies FANCM as a likely high grade serous ovarian cancer susceptibility gene (2017) Oncotarget; Meeks, H.D., Song, H., Michailidou, K., Bolla, M.K., Dennis, J., Wang, Q., BRCA2 polymorphic stop codon K3326X and the risk of breast, prostate, and ovarian cancers (2015) J Natl Cancer Inst, 108 (2); Nieuwenhuis, M.H., Vasen, H.F., Correlations between mutation site in APC and phenotype of familial adenomatous polyposis (FAP): a review of the literature (2007) Crit Rev Oncol Hematol, 61 (2), pp. 153-161; (2017), for NICE. Care of People at Risk of Familial Breast Cancer and Management of Breast Cancer and Related Risks in People with a Family History of Breast Cancer. Clinical guideline [CG164] Published date: June 2013; Last updated: March; http://www.nccn.org, National Comprehensive Cancer Network: NCCN guidelines genetic/familial high-risk assessment: Breast and ovarian, version 1.2018UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85038919505&doi=10.1016%2fj.breast.2017.12.013&partnerID=40&md5=2bdafc8e67fb9240e2a6f92f11cd43fe",
year = "2018",
doi = "10.1016/j.breast.2017.12.013",
language = "English",
volume = "38",
pages = "92--97",
journal = "Breast",
issn = "0960-9776",
publisher = "Churchill Livingstone",
}